LSRF Surges on Renewed State‑Backed Momentum in Traditional Chinese Medicine

The Shanghai‑based ETF 鹏华中药 (159647) recorded a gain of 3.57 % on July 13, 2026, with its constituent 陇神戎发 (LSRF) posting a 20 % jump in intraday trading. The rally was driven by the 国务院’s endorsement of the “中医药振兴发展十五五规划”, signalling a top‑level push to modernise and globalise traditional Chinese medicine (TCM) while maintaining parity with Western therapeutics.

Policy Context

  • State Endorsement: The Ministry’s approval of the 2025‑2030 plan provides a clear top‑down roadmap for TCM development, covering research, manufacturing, and market expansion.
  • New Basic Drug Catalogue: After an eight‑year hiatus, the catalogue has expanded to include 48 new compounds, raising the proportion of traditional compound preparations (中成药) to roughly 40 %. This policy shift favours products with robust evidence bases and focused indications—exactly the profile of LSRF’s flagship offerings.
  • Innovation Incentives: The plan explicitly supports the cultivation of innovative TCM drugs, encouraging companies to build evidence chains and pursue niche disease areas, such as paediatric and chronic conditions.

Market Reaction

  • Index Performance: The 中证中药指数 (930641) rose 3.56 %, lifting its top ten holdings—云南白药, 片仔癀, 东阿阿胶, 吉林敖东, 众生药业, 同仁堂, 华润三九, 白云山, 以岭药业, 达仁堂—by an average of 5‑15 %.
  • Peer Moves: Alongside LSRF, 九芝堂 and 哈药股份 hit the daily limit, while 上海凯宝 and 新赣江 gained over 10 %. The sector’s breadth underscores a systemic bullish sentiment rather than a single‑company anomaly.

LSRF’s Position

With a market cap of 2.28 billion CNY and a PE ratio of 46.19, LSRF sits at a valuation premium relative to the broader sector, reflecting investor expectations of continued growth. Its close price of 7.50 CNY on July 9, 2026, sits comfortably above the 52‑week low of 6.78 CNY, yet below the 52‑week high of 12.9 CNY set on August 3, 2025.

The company’s dual focus on traditional Chinese and Western medicines positions it strategically to capitalize on the policy shift toward a blended healthcare model. Recent product pipelines—particularly those targeting high‑prevalence chronic illnesses—align with the new basic drug list’s emphasis on clinically validated TCM formulations.

Forward Outlook

  • Immediate Impact: The policy announcement is expected to lift the 销售放量 (sales volume) of clinically proven TCM drugs across primary care settings. LSRF, with its strong evidence base, should see an uptick in sales momentum in the short term.
  • Long‑Term Growth: As the 15‑year plan unfolds, continued investment in R&D and international expansion will likely sustain the company’s growth trajectory. The broadened drug catalogue and heightened focus on innovation provide a fertile ground for new product launches and market diversification.

In sum, LSRF’s recent surge is a direct response to the 国务院’s strategic push for TCM modernisation. Coupled with a supportive policy environment and the company’s alignment with evidence‑driven product development, the firm is well‑positioned to ride the wave of renewed interest in traditional Chinese medicine.